Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 376Polycystic Ovary Syndrome 40Neoplasm Metastasis 23Endometrial Neoplasms 22Ovarian Neoplasms 16Neoplasms 14Infertility 11Advanced Breast Cancer 10Fallopian Tube Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Triple Negative Breast Neoplasms 7Recurrence 7Osteoporosis 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Breast Diseases 7Carcinoma, Lobular 6Breast Carcinoma In Situ 6Prostatic Neoplasms 5Leiomyoma 4Infertility, Female 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Arthralgia 4Obesity 3Neoplasms, Hormone-Dependent 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2

Interventions

Methotrexate 4Vacuum Curettage 3merphos 2Drug Therapy 2Dactinomycin 2Vitamin B Complex 1Suction 1Pemetrexed 1Leucovorin 1Letrozole 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hydatidiform Mole × Letrozole × Clear all
NCT05203562 2022-07-12

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Zagazig University

Phase 2/3 Unknown
200 enrolled
Gynecologic

Hydatidiform Mole, Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡